STATE DISCLOSURES: VERMONT, COLORADO & CONNECTICUT
Vermont Disclosure Act
Vermont law 33 V.S.A. §2005a mandates that pharmaceutical manufacturers disclose to Vermont physicians and other prescribers the average wholesale price (AWP) of drugs they market within the state as well as the prices of other drugs in the same therapeutic class. Under Vermont law, “therapeutic class” is defined as the therapeutic class listed in the 2004 American Hospital Formulary Service Pharmacologic-Therapeutic Classification published by the American Society of Health System Pharmacists (available at http://www.ashp.org).
ORSERDU: VT Short Form
Colorado Disclosure Act
Colorado law HB 19-1131 requires pharmaceutical manufacturers, when engaging in prescription drug marketing, to provide the wholesale acquisition cost (WAC) of the drug to Colorado prescribers. Under Colorado law, the names of generic prescription drugs (if available) from the same therapeutic class (i.e., same or similar mechanism of action used to treat a specific condition) shall also be provided.
ELZONRIS: Colorado Form
ORSERDU: Colorado Form
CONNECTICUT DISCLOSURE ACT
Connecticut Public Act No. 23-171 requires pharmaceutical representatives engaged in legend drug marketing in Connecticut to disclose the list price. A list price may also be known as the Wholesale Acquisition Cost (“WAC”). Under Connecticut law, a “legend drug” is defined as a drug that is required by any applicable federal or state law to be dispensed pursuant only to a prescription or is restricted to use by prescribing practitioners only or is required to bear “RX ONLY” in accordance with the federal Food, Drug, & Cosmetic Act.